Try our mobile app

BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results

Published: 2020-02-26 21:05:00 ET
<<<  go to BMRN company page

- Full-year 2019 Total Revenues Increased 14% to $1.7 billion

- 17% Increase in Net Product Revenues from Products Marketed by BioMarin to $1.6 billion in Full-year 2019

- 2020 Full-year Total Revenue Growth Expected to be Between 14% and 20%

- For the Full-year 2020 BioMarin Expects for the First Time to be Profitable on a GAAP Basis

- U.S. and European Marketing Submissions for Valoctocogene Roxaparvovec for Severe Hemophilia A Accepted by FDA and EMA under Priority Review and Accelerated Assessment, Respectively; Approval Decisions Expected in Second Half of 2020

- Phase 3 Study with Vosoritide for Achondroplasia Demonstrated Highly Statistically Significant Increase (p